Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)
- Status
- TERMINATED
- Phase
- PHASE2
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer
- Status
- COMPLETED
- Phase
- PHASE2
PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection
- Status
- COMPLETED
- Phase
- PHASE1
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
- Status
- WITHDRAWN
- Phase
- PHASE2
Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Phase Ib of L-NMMA and Pembrolizumab
- Status
- COMPLETED
- Phase
- PHASE1
Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE2
Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
UCDCC#269: A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC.
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes
- Status
- COMPLETED
- Phase
- PHASE2
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)
- Status
- WITHDRAWN
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)
- Status
- COMPLETED
- Phase
- PHASE3
Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1